In fact, in the disease remission state, CD8+ PD-1+ T cells were decreased in the peripheral blood of patients with MS and resolved in patients treated with IFN-β treatment who showed immune-regulatory cytokine interleukin (IL)-10 expression. The gene discussed is CD8A; the disease is myeloid sarcoma.